Aug 21, 2026·Score 89·Type A — Value-style analysisUsed for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$108.44
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$90.00($85.00–$95.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$115.00
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type A - Haemonetics Corporation (HAE) 20260821 Stock Analysis
📅 Haemonetics Key Upcoming Events
November 05, 2026Q2 2027 Earnings Release (Estimated)
Description: The market will closely monitor sequential organic revenue growth within the newly aligned Apheresis and MedSurg segments, paying particular attention to the ongoing commercial traction of the VASCADE MVP XL system and the margin uplift from Persona PLUS software adoption across the global plasma collection footprint.
February 04, 2027Q3 2027 Earnings Release (Estimated)
Description: Investors will focus heavily on free cash flow conversion and debt reduction metrics following the previous year’s aggressive M&A activity (OpSens and Vivasure), as well as looking for updates on the volume trajectory related to the CSL Plasma non-exclusive supply agreement transition.
May 06, 2027Q4 2027 Earnings Release (Estimated)
Description: Full-year fiscal 2027 results will definitively confirm whether the company achieved its upwardly revised guidance of 5-8% reported revenue growth and 50-100 basis points of adjusted operating margin expansion, serving as a critical validation of the overarching corporate transformation strategy.
🏢 Step 1: Haemonetics Company Overview & Business Model
Q1-A1. What is Haemonetics?
Company Name (Ticker): Haemonetics Corporation (HAE)
Sector: Healthcare
Exchange: NYSE
Founded: Month DD, 1971
Listing Date: May 09, 1991
Fiscal Year End: March
Headquarters: United States, Boston
CEO: Christopher A. Simon
Market Cap: $4.93B
Shares Outstanding: 45.50M
Current Stock Price:$108.44
Annual Dividend Yield: ➖ Not applicable
Ex-dividend Date: ➖ Not applicable
As-of: August 21, 2026 (ET)
Q1-A2. How Does Haemonetics Make Money?
Core Business Model: Haemonetics operates a highly lucrative, classic “razor-and-blade” recurring revenue model within the global medical technology sector. The company provides specialized capital equipment systems (the razors) and generates the vast majority of its high-margin revenue from the continuous sale of proprietary, single-use consumables, reagent cartridges, and advanced software subscriptions (the blades) required to operate those systems.
Target Customers: The company serves a diverse but highly specialized client base, including massive global plasma fractionators (such as CSL Plasma), large hospital networks, regional blood banks, and specialized surgical suites. Its reach extends across approximately 95 countries, though North America remains the dominant revenue engine, particularly given that the United States collects roughly two-thirds of the world’s source plasma.
Value Proposition: By deploying Haemonetics’ automated plasma collection systems (like the NexSys PCS) paired with proprietary donor management software (Persona PLUS), commercial collection centers can significantly increase plasma yield per donor while simultaneously reducing procedure times and optimizing operational overhead. In the hospital setting, its Interventional Technologies (VASCADE) and Blood Management Technologies (TEG analyzers, Cell Saver systems) accelerate patient ambulation, reduce severe bleeding complications, and significantly shorten costly hospital stays, delivering measurable health economics and outcomes research (HEOR) value to healthcare providers.
Q1-A3. Haemonetics’s Revenue Segments & Core Income Sources
Apheresis Segment (approx. 56% of Revenue): Following a strategic financial reporting restructure in June 2026, this segment combines the legacy Plasma and Blood Center divisions into a single unified unit. This segment acts as the company’s historical cash cow, driven by the ubiquitous NexSys PCS plasmapheresis equipment, recurring plastic disposables, and the rapidly expanding Persona PLUS software platform. While operating in a mature and highly consolidated market, this segment generates the immense free cash flow required to fund the company’s broader corporate expansion, continuing to grow organically at mid-single digits despite aggressive customer transition periods.
MedSurg Segment (approx. 44% of Revenue): Formerly known as the Hospital segment, this rebranded division encompasses Blood Management Technologies (TEG viscoelastic analyzers, Cell Saver autologous blood recovery systems) and Interventional Technologies (VASCADE vascular closure devices, OpSens sensor-guided guidewires). MedSurg represents Haemonetics’ primary structural growth engine, featuring significantly higher gross margins, durable double-digit growth in key franchise product lines, and a rapidly expanding total addressable market (TAM) fueled by the explosion in complex electrophysiology and structural heart procedures.
Q1-A4. Who Are Haemonetics’s Competitors?
Direct Competitors (Plasma & Blood Collection): In the global plasma and whole blood separation markets, Haemonetics primarily battles against specialized medical suppliers such as Fresenius Kabi, Terumo BCT, and Macopharma. Haemonetics maintains a dominant leadership position, particularly in North America, by leveraging its deeply entrenched software ecosystem (NexSys) to create exceptionally high switching costs that deter collection centers from transitioning to competitor hardware.
Direct Competitors (Hospital & Interventional): Within the vascular closure and sensor-guided technology markets, the company faces off against massive, diversified medical device conglomerates including Abbott Laboratories, Medtronic, and Teleflex. While possessing a smaller overall footprint, Haemonetics effectively outcompetes these larger rivals in specific niches by utilizing highly specialized, best-in-class products (such as the VASCADE MVP XL designed specifically for large-bore venous closure) to win dedicated electrophysiology purchasing contracts.
Industry Position: Haemonetics operates as the undisputed technological tollbooth of the global plasma collection industry while simultaneously acting as a rapidly ascending, agile challenger in high-growth interventional cardiology. The company brilliantly uses the robust, reliable cash flows from its legacy plasma monopoly to fund its deliberate transformation into a diversified, high-margin med-tech compounder.
Q1-A5. Haemonetics Key Events: Past 12 Months
December 12, 2025Closed the $345 million acquisition of OpSens Inc.
Description: Haemonetics completed its all-cash acquisition of OpSens for approximately $255 million in equity value ($345 million enterprise value), integrating highly innovative fiber-optic sensor technology and the OptoWire product line into its Interventional Technologies portfolio, thereby significantly expanding its footprint and clinical relevance within the attractive interventional cardiology market.
January 09, 2026Announced the acquisition of Vivasure Medical Limited
Description: The company dramatically accelerated its vascular closure dominance by acquiring Ireland-based Vivasure Medical for an upfront cash payment of €100 million (with an additional €85 million tied to contingent milestones). This acquisition secured Vivasure’s next-generation, fully absorbable technology (PerQseal) for percutaneous vessel closure, opening a pathway into the massive large-bore arterial closure market.
March 02, 2026Repaid $300 million of 2026 Convertible Senior Notes
Description: Demonstrating robust liquidity and meticulous balance sheet management, Haemonetics retired the remaining principal of its 2026 convertible senior notes at maturity using cash on hand and its revolving credit facility, effectively eliminating a significant near-term debt overhang and preventing shareholder dilution.
June 05, 2026Updated financial reporting to a two-segment structure
Description: Management streamlined operations by proactively combining the legacy Plasma and Blood Center units into a single “Apheresis” segment and renaming the Hospital unit to “MedSurg”. This strategic realignment better matches external financial reporting with internal capital allocation strategies, providing clearer visibility into the hospital suite’s growth.
August 06, 2026Q1 2027 Earnings Release
Description: The company reported an impressive fiscal first quarter, delivering $339.4 million in net revenue (up 5.6% YoY) and raising full-year revenue growth guidance to 5-8%. This outperformance was propelled by a stunning 25% surge in North American plasma disposables and highly resilient MedSurg adoption, proving the underlying strength of the core business.
August 14, 2026Entered a non-exclusive supply agreement with CSL Plasma
Description: Haemonetics secured a major, albeit non-exclusive, supply agreement allowing CSL Plasma to continue utilizing NexSys PCS devices and Persona PLUS technology across multiple U.S. centers. While removing exclusivity, the deal clarifies the long-term relationship trajectory with its largest customer and eliminates a massive overhang of uncertainty regarding future volume retention.
Q1-A6. Step 1 Key Takeaways
Step 1 Summary: Haemonetics is flawlessly executing a complex corporate transformation, deliberately channeling the immense, durable cash flows generated from its monopolistic plasma collection business to fund aggressive M&A and organic expansion into high-margin, double-digit growth interventional cardiology and hospital markets.
Top 3 Red Flags:
1 The ongoing structural transition of CSL Plasma (a foundational anchor customer) away from exclusive reliance on Haemonetics introduces long-term volume risk and pricing pressure in the core Apheresis segment.
2 The company carries a substantial absolute debt load of $1.17 billion following a string of recent, aggressive acquisitions, which increases interest expense sensitivity in a prolonged “higher for longer” macroeconomic environment.
3 MedSurg operating margins face near-term, acute pressure from global tariff impacts, elevated freight costs, and the naturally dilutive integration phases of recent acquisitions (such as OpSens and Vivasure).
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 North American Plasma Disposables Volume Growth
2 VASCADE Product Line Revenue Growth (Interventional Technologies)
3 Persona PLUS Software Adoption Rates and Yield Improvement Metrics
5 Free Cash Flow Conversion Ratio (Management Targeting ≈80% of adjusted net income)
Top 3 Unconfirmed and Estimated:
1 The ultimate terminal plateau of VASCADE MVP XL market penetration within the rapidly evolving electrophysiology space.
2 The exact timeline and FDA Premarket Approval (PMA) realization for Vivasure Medical’s revolutionary PerQseal Elite technology.
3 The long-term stabilization floor of the company’s gross margin once acute supply chain and tariff disruptions fully normalize across the global footprint.
🏰 Step 2: Haemonetics’s Economic Moat, Growth & Capital Allocation
Q2-A1. Does Haemonetics Have a Durable Economic Moat?
Entry barriers: Haemonetics benefits from formidable, nearly insurmountable switching costs in its core Apheresis division. Its NexSys PCS hardware is deeply integrated with its proprietary donor management software (Persona PLUS) across hundreds of global plasma collection centers. Replacing this mission-critical infrastructure would require a competitor to not only match the hardware’s exact extraction efficiency but also force the client to endure massive operational disruptions, extensive staff retraining protocols, and brutal FDA recertification procedures.
Pricing power: While the global plasma collection market features highly concentrated buyer power (dominated by a few massive fractionators like CSL, Grifols, and Takeda), Haemonetics’ introduction of Persona PLUS software—which demonstrably and consistently increases plasma yield per donor by over 5%—allows the company to capture immense value. By selling premium software subscriptions that directly improve the customer’s bottom line, Haemonetics exercises strong pricing power rather than solely competing in a race-to-the-bottom on disposable plastic pricing.
Intangible assets: The company possesses a highly robust patent portfolio and exclusive FDA clearances, particularly concentrated in its MedSurg division. The VASCADE MVP XL remains a highly differentiated, proprietary solution for large-bore venous closure in electrophysiology, effectively blocking generic substitutes, dominating the standard of care, and preserving exceptionally high gross margins.
Q2-A2. Is Haemonetics’s Growth Sustainable?
Market Outlook & TAM: The global plasma collection market is experiencing steady, structural, and seemingly recession-proof growth driven by the insatiable global clinical demand for immunoglobulin (Ig) therapies and plasma-derived medicines. Concurrently, the MedSurg total addressable market (TAM) is expanding rapidly; the TEG franchise addresses an underpenetrated $400 million TAM, while the booming electrophysiology and structural heart markets provide massive, multi-decade structural tailwinds for the Vascular Closure product portfolio.
Growth Sustainability: Growth is decidedly structural, not cyclical. The company is actively and successfully shifting its overall revenue mix toward high-growth Hospital (MedSurg) products, utilizing its legacy cash flows to acquire innovative, synergistic assets (Attune Medical, OpSens, Vivasure) that immediately plug into Haemonetics’ established global commercial sales infrastructure, guaranteeing sustainable cross-selling growth.
Downside Scenarios:1 A sudden, catastrophic FDA recall or severe regulatory sanction regarding the NexSys PCS devices could freeze global collections. 2 The faster-than-expected commercialization of a synthetic or recombinant alternative to human plasma could permanently destroy the Apheresis TAM. 3 A total failure to successfully integrate and achieve regulatory clearance for pipeline acquisitions like Vivasure could result in massive goodwill impairment and a collapse of the MedSurg growth narrative.
Q2-A3. How Does Haemonetics Allocate Capital & Return Cash?
Capital Allocation: Management exhibits a highly disciplined, shareholder-aligned, and transparent capital allocation strategy. Their explicitly stated primary focus is organic R&D investment, immediately followed by targeted, bolt-on M&A (OpSens, Vivasure) designed to rapidly expand the MedSurg TAM. Excess free cash flow is then aggressively and mechanically directed toward debt reduction and massive share repurchases.
Shareholder Returns: While Haemonetics does not pay a regular dividend, it executes massive, highly accretive share repurchases. During fiscal 2026, the company repurchased 3.01 million shares for $175 million under a massive $500 million authorization, fundamentally shrinking the outstanding float and systematically driving EPS accretion for long-term holders.
Reinvestment Efficacy: The company generates excellent, peer-beating capital efficiency. ROIC stands robustly between 7.82% and 8.84% (depending on specific quarter-end working capital fluctuations), which comfortably and consistently exceeds its Weighted Average Cost of Capital (WACC) of 5.98%, definitively confirming that management is actively creating intrinsic shareholder value with its retained earnings and aggressive M&A strategy.
Q2-A4. Step 2 Key Takeaways
Scoring Rationale:
Economic Moat (8/10): Extremely high switching costs and mission-critical software integration provide a wide moat, though the concentrated buyer power of massive plasma fractionators prevents a perfect score.
Growth Sustainability (7/8): Powerful, multi-decade structural tailwinds in both plasma-derived therapies and interventional cardiology ensure highly sustainable growth, backed by an aggressively expanding addressable market.
Capital Allocation (7/7): Management perfectly balances strategic, TAM-expanding M&A with aggressive share repurchases and responsible debt reduction, consistently generating an ROIC well above the cost of capital.
Growth and Revenue Indicators: Over the past five years, Haemonetics has engineered a comprehensive margin and earnings transformation. Fiscal 2026 recorded $1.33 billion in revenue, coupled with a massive adjusted EPS expansion to $4.96. While reported revenue dipped slightly (-2.0%) due to strategically planned divestitures and the ongoing CSL transition, underlying organic growth (excluding CSL) surged a remarkable 9.5% in FY26. Q1 FY27 continued this relentless momentum with 5.9% organic growth and adjusted EPS of $1.14.
Profitability Margin and Leverage: The company is executing a textbook operating leverage narrative. By relentlessly pushing higher-margin MedSurg products and premium Persona PLUS software subscriptions, adjusted gross margins have structurally expanded to sit comfortably near 60%. Adjusted operating margins expanded by a full 140 basis points in FY26 to reach 25.4%, proving the company can successfully offset acute supply chain and freight inflation while dropping incremental revenue straight to the bottom line.
Q3-A2. How Profitable Is Haemonetics? (Margins & ROIC)
ROIC vs WACC: Haemonetics generates a highly value-accretive Return on Invested Capital (ROIC) of 8.84% (TTM basis), which significantly exceeds its Weighted Average Cost of Capital (WACC) of 5.98%.
Industry Superiority: This positive spread confirms that the company is genuinely compounding intrinsic value. Crucially, its aggressive acquisition strategy (buying OpSens, Vivasure, and Attune) has not diluted core efficiency; instead, plugging these new interventional devices into the existing, highly efficient hospital salesforce creates immediate accretive margin benefits, showcasing a clear operational advantage over smaller, single-product med-tech peers.
Q3-A3. What Drives Haemonetics’s Returns? (ROIC Breakdown)
Manufacturing and Hardware Industry Efficiency: As a medical device manufacturer operating a razor-and-blade model, Haemonetics’ primary efficiency driver is its installed base utilization rate. The company places expensive capital equipment (such as NexSys PCS in plasma centers or TEG analyzers in hospitals) into facilities, then generates massive, high-margin ROIC through the continuous, recurring sale of proprietary plastic disposables, reagent cartridges, and software subscriptions attached exclusively to those machines. The more frequently a center collects plasma or a hospital runs a viscoelastic test, the faster Haemonetics’ capital turns over into pure, high-margin profit.
Q3-A4. Are Haemonetics’s Earnings High Quality?
Cash Flow vs Net Income: Earnings quality is absolutely exceptional. In fiscal 2026, free cash flow skyrocketed 45.2% to $209.9 million, representing an incredibly healthy 89% conversion rate from adjusted net income.
Cash Conversion Rate: Operating cash flow consistently exceeds GAAP net income by a wide margin. In Q1 FY27, net cash from operating activities reached $52.3 million compared to GAAP net income of $33.0 million, driven entirely by disciplined working capital execution and robust accounts receivable collections. There is absolutely no evidence of fictitious earnings; the reported profits convert directly to hard, deployable cash.
Q3-A5. Is Haemonetics’s Balance Sheet Healthy? (Debt & Leverage)
Financial Stability and Debt Structure: Following a deliberate sequence of aggressive, TAM-expanding acquisitions, Haemonetics carries a total debt load of $1.17 billion against cash and equivalents of $223.4 million, resulting in a net debt position of roughly $950 million.
Leverage and Refinancing Risk: Despite the optically high absolute debt figure, the balance sheet remains fundamentally sound. Net leverage sits at a highly manageable 2.69x EBITDA, and the company maintains an interest coverage ratio of 9.3x, ensuring that operating profits easily and safely cover all debt service requirements. Liquidity is pristine, fortified by $498.7 million in available revolving credit and the successful, seamless cash repayment of its $300 million 2026 convertible notes at maturity.
Q3-A6. Step 3 Key Takeaways
Scoring Rationale:
Profitability·Capital Efficiency (9/10): Gross margins near 60% and a commanding, positive ROIC-WACC spread demonstrate excellent core profitability, with only slight deductions for temporary tariff-related gross margin headwinds.
Cash Flow·Profit Quality (8/8): Phenomenal free cash flow conversion rates approaching 90% definitively prove that reported earnings are backed by undeniable, high-quality cash generation.
Financial Soundness·Debt Management (5/7): While cash generation and interest coverage are superb, absolute debt levels over $1.1 billion and a 2.69x leverage ratio introduce moderate, undeniable balance sheet friction in a higher-for-longer interest rate environment.
Q4-A1. Does Haemonetics Have Accounting Red Flags?
Revenue recognition: not found
Evidence: The company’s strategic transition from upfront software license revenue recognition to ratable SaaS-like models has been fully disclosed, entirely transparent, and accurately reflected in year-over-year gross margin normalizations without any obfuscation.
Cost capitalization: not found
Evidence: R&D expenditures and aggressive acquisition integration costs are expensed cleanly through the income statement, with exceedingly clear non-GAAP reconciliation tables provided for one-time M&A adjustments.
Sharp increase in accounts receivable and inventory: not found
Evidence: Q1 FY27 operating cash flow specifically benefited from highly favorable working capital adjustments, entirely driven by the timely and efficient collection of receivables, indicating robust end-market channel health.
Non-recurring adjustment (normalization): not found
Evidence: Adjusted metrics logically and consistently exclude standard acquisition amortizations, necessary restructuring, and divestiture impacts without artificially inflating the perception of core operational health.
Q4-A2. Is Haemonetics Overspending? (Capex & Capital Cycle)
➖ Not applicable: The capital-cycle/oversupply lens does not apply to this medical device manufacturer, as its CapEx is primarily directed toward high-ROI R&D, software development, and targeted M&A rather than massive, heavy-industry physical capacity expansions that are prone to sudden, margin-crushing cyclical gluts.
Q4-A3. How Sound Is Haemonetics’s Cash Flow?
Cash Flow Quality: Operating cash flow consistently matches or wildly exceeds net income. The company is absolutely not reliant on financing activities to fund daily operations; instead, its organic operations throw off massive excess cash that actively funds its financing activities, specifically allowing for aggressive debt paydown and continuous share repurchases. No warning signals or synthetic cash flow distortions are present.
Q4-A4. Is Haemonetics Diluting Shareholders?
Confirmed (Past) Dilution: Management is actively, aggressively fighting dilution. Over fiscal 2026, the company successfully repurchased over 3.01 million shares for $175 million, physically shrinking the outstanding share count to 45.50 million and manufacturing direct EPS accretion.
Potential (Future) Dilution & Overhang: The company holds 2029 Convertible Senior Notes, which carry inherent dilution risk if the stock price surges. However, management brilliantly executed concurrent Capped Call transactions with strike prices around $117.12 and cap prices of $180.18, effectively and mechanically neutralizing equity dilution up to extreme upside scenarios. Furthermore, the remaining $325 million in the current share repurchase authorization provides a massive structural defense against any minor overhang.
Q4-A5. Data Integrity Check
Period: Trailing Twelve Months (TTM) used for valuation multiples; fiscal year standardization verified ➡ (Pass)
Definition: GAAP/Non-GAAP and FCF definitions, formulas, and adjustments unified across sources ➡ (Pass)
Number of shares: Diluted weighted average shares utilized for EPS calculations, unified with SBC inclusion ➡ (Pass)
Unit: USD currency, exact thousands/millions unit definitions unified ➡ (Pass)
Single Value Confirmation: A single, consistent value was verified across SEC regulatory filings and independent financial platforms ➡ (Pass)
Q4-A6. Step 4 Key Takeaways
Scoring Rationale:
Accounting anomalies·distortion signals (8/8): Financial statements are completely clean, meticulously transparent, and accurately reflect the underlying operational realities of the business.
Cash flow warning signals (7/7): Cash flow generation is pristine, easily and continuously covering operating needs while fueling massive capital returns to shareholders.
Dilution factors (5/5): Management is actively retiring shares, reducing the float, and utilizing complex capped calls to aggressively and successfully defend against convertible debt dilution.
Step 4 Summary: Haemonetics presents a flawless forensic profile, characterized by highly transparent accounting, exceptional real cash generation, and a fiercely shareholder-friendly anti-dilution framework.
Q5-A1. Can You Trust Haemonetics’s Management? (Guidance Track Record)
Guidance Hit Rate: CEO Christopher Simon and CFO James D’Arecca have established formidable, unassailable credibility with Wall Street. Following a stellar FY26 that successfully met highly complex transformation goals, management delivered a massive Q1 FY27 beat-and-raise, lifting full-year organic revenue guidance to 4-7% and cementing immense institutional trust in their forecasting precision.
Transparency and Consistency: Management proactively addresses headwinds without hiding behind jargon. They openly discuss the financial impact of the CSL Plasma transition, accurately guide the market on the exact margin pressures stemming from global tariffs, and executed a highly transparent segment reorganization to map directly to their internal capital allocation strategies.
Q5-A2. What Are Haemonetics Insiders Doing?
Insider Trading Status: According to recent 13F and Form 4 filings, insider activity remains exceptionally quiet but leans decidedly positive. Over the trailing 12 months, insiders engaged in approximately $0.1 million in net open-market buying with absolutely zero recorded insider selling.
Evaluating Confidence Signals: While the absolute dollar volume of insider buying is relatively low compared to the market cap, the complete, absolute absence of insider liquidation—especially as the stock hovers near 52-week highs—indicates profound executive confidence in the ongoing MedSurg transformation, the pipeline execution, and the long-term intrinsic value of the equity.
Q5-A3. Is Haemonetics’s Management Aligned With Shareholders?
Performance and Compensation Indicators: Haemonetics utilizes a textbook, highly aligned pay-for-performance executive compensation model. Short-term incentives are strictly gated by rigorous, highly visible financial metrics: adjusted revenue, adjusted EPS, and free cash flow generation (resulting in a 133.4% payout for the massive FY26 outperformance).
Incentive Alignment Assessment: Long-term equity grants heavily feature Performance Share Units (PSUs) tied directly to relative Total Shareholder Return (TSR) against the S&P MidCap 400. Combined with strict executive stock ownership guidelines and a robust clawback policy, executive wealth creation is entirely, mechanically dependent on sustained, peer-beating stock price appreciation.
Q5-A4. Step 5 Key Takeaways
Scoring Rationale:
Management Trust (5/5): Leadership consistently beats rigorous expectations, proactively raises guidance, and communicates complex headwinds with institutional-grade transparency.
Insider Trends (4/5): The complete lack of insider selling near 52-week highs is highly bullish, though the absolute dollar volume of buying is too small to warrant a perfect score.
Governance·Compensation System (4/5): The compensation framework is perfectly tied to FCF and relative TSR, ensuring management only reaps massive rewards when shareholders do.
Step 5 Summary: Haemonetics is led by a highly credible, execution-oriented management team whose compensation is aggressively linked to raw cash flow generation and relative shareholder returns, operating with complete transparency.
⛵ Step 6: Haemonetics Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Haemonetics Guidance
Guidance gap and direction analysis: Market sentiment is overwhelmingly positive and accelerating. Following the massive Q1 FY27 earnings beat ($1.14 actual vs. $1.08 consensus), Haemonetics actively raised its own full-year guidance, forcing Wall Street analysts into an aggressive upward revision cycle. Top-tier brokerages including Baird, BTIG, and Barrington immediately raised price targets well above $110, explicitly citing unassailable cash flow generation and unstoppable MedSurg momentum.
Q6-A2. What Is Haemonetics’s Short Interest?
Institutional Trends: Institutional ownership is incredibly dense and committed, standing at 99.67%, indicating that nearly the entire float is locked away in high-conviction, long-term institutional portfolios, providing a massive structural floor for the equity.
Short Selling Indicators: Short interest sits at 6.56% of the float (roughly 2.92 million shares), with a Days-to-Cover ratio of 4.57. While not extreme enough to trigger an immediate short squeeze, this slightly elevated Days-to-Cover suggests a persistent, localized cohort of short sellers betting against the stock, likely anchored to lingering fears surrounding the CSL Plasma transition or the broader macro debt load.
Q6-A3. Step 6 Key Takeaways
Scoring Rationale:
Consensus vs Guidance (3/3): Management’s proactive guidance raise forced a massive wave of analyst target upgrades, demonstrating perfect fundamental momentum and narrative control.
Supply·Short Interest (1/2): Massive institutional backing provides a rock-solid floor, but the 4.57 days-to-cover short interest introduces slight but undeniable trading friction.
Step 6 Summary: Market sentiment is highly constructive and upward-trending, characterized by relentless analyst upgrades following earnings beats, heavily supported by near-total institutional ownership.
🚀 Step 7: Haemonetics Catalysts & Price Triggers
Q7-A1. What Could Move Haemonetics Stock? (Top 3 Catalysts)
1 Accelerated Commercial Adoption of Persona PLUS Software
Timing: Next 6-12 months
Success Conditions: Management proves the software consistently yields an excess of 5% more plasma per donor across the U.S. installed base, allowing Haemonetics to rapidly monetize its legacy hardware footprint via high-margin SaaS-like software subscriptions, fundamentally shifting the corporate gross margin profile upward.
Failure Risk: Plasma fractionators push back aggressively against software pricing premiums, prioritizing sheer foot-traffic volume through competitor machines over individualized yield optimization.
2 VASCADE MVP XL Electrophysiology Market Capture
Timing: Next 6-12 months
Success Conditions: Following recent FDA label expansions, the MVP XL definitively establishes itself as the undisputed standard of care for large-bore (10-12F) venous closures in booming AFib and structural heart procedures, driving sustained double-digit MedSurg growth and immense operating leverage.
Failure Risk: Larger, heavily capitalized cardiovascular giants (like Abbott or Medtronic) aggressively bundle generic closure devices with their ablation catheters, squeezing Haemonetics out of lucrative, exclusive hospital purchasing contracts.
3 Integration and Commercialization of Vivasure’s PerQseal Elite
Timing: Next 6-12 months
Success Conditions: The company secures vital regulatory milestones (including rapid FDA PMA progress) for Vivasure’s fully absorbable percutaneous vessel closure technology, instantly expanding its TAM into massive new cardiovascular arterial closure verticals.
Failure Risk: Regulatory delays, unforeseen clinical trial complications, or adverse patient outcomes force Haemonetics to write down the massive €100M+ acquisition, damaging management’s M&A credibility and halting momentum.
Q7-A2. Haemonetics’s Earnings Revision Trend
Earnings expectations and momentum: The earnings revision trend is incredibly strong and slopes steeply upward. Following the Q1 FY27 print in August 2026, analysts aggressively revised EPS estimates upward, reflecting the company’s unexpected 6% organic growth and highly disciplined cost controls. The consensus EPS for the current fiscal year is steadily tracking toward the $5.74 range, definitively confirming that institutional models are catching up to the reality of the company’s MedSurg margin transformation.
Q7-A3. Step 7 Key Takeaways
Scoring Rationale:
Catalyst (6/7): The combination of software monetization in the legacy plasma business and explosive TAM expansion in the Interventional business creates a highly asymmetric, low-risk catalyst path with multiple ways to win.
EPS Trend (2/3): Revisions are solidly positive and upward-sloping, driven by consistent, methodical beat-and-raise quarters that force analysts to constantly play catch-up.
Step 7 Summary: Haemonetics possesses a formidable arsenal of powerful, near-term catalysts, heavily weighted toward high-margin software adoption and the rapid commercialization of best-in-class cardiovascular closure devices.
⚖️ Step 8: Is Haemonetics Fairly Valued? Valuation Analysis
Scoring Rationale: While the trailing P/E is optically distorted by GAAP acquisition and restructuring charges, the forward P/E of 19.33x, combined with a highly attractive P/FCF of 16.35x and an EV/EBITDA under 15x, paints the definitive picture of a reasonably cheap medical device compounder relative to its immense cash flow generation capability.
📌 (1) Axis Q8-A1 Score:1
Q8-A2. Haemonetics vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER
Calculation of peer-to-peer deviation rate: -0.91%
Scoring Rationale: Compared against a meticulously matched peer basket of mid-cap medical device and specialized healthcare equipment manufacturers (e.g., MMSI, TFX), Haemonetics’ 19.33x Forward P/E trades in virtually perfect lockstep with the peer average of ≈19.50x, reflecting absolute fair value within its specific industry cohort.
📌 (2) Axis Q8-A2 Score:0
Q8-A3. Is Haemonetics Cheap or Expensive vs Its History?
Comparison Indicators: P/FCF
Scoring Rationale: Over the past five years, Haemonetics’ P/FCF multiple has swung wildly due to the pandemic, supply chain shocks, and aggressive restructuring, peaking near 58x. However, its current P/FCF of 16.35x sits comfortably in the bottom 20-40% of its historical trailing 5-year band, unequivocally signaling that the market is severely undervaluing its newly optimized, highly efficient cash-conversion engine.
📌 (3) Axis Q8-A3 Score:2
Q8-A4. What Growth Is Priced Into Haemonetics? (Reverse DCF)
Implied Growth Rate:6.5%
1 Methodology: PEG-based Inversion
2 Core assumptions: Applying the current Forward P/E of 19.33x against a normalized, conservative med-tech PEG baseline of ≈1.5x implies the market expects roughly 6.5% annualized EPS growth over the medium term to justify the current price.
Achievable Growth Rate:8.6%
Basis: Analyst consensus for medium-term EPS CAGR sits at approximately 8.66%, heavily supported by the structural margin expansion expected from the MedSurg shift and aggressive, ongoing debt paydown.
Scoring Rationale: The market is currently pricing in a highly conservative growth trajectory that Haemonetics should easily clear, providing a comfortable margin of safety and exceedingly low growth difficulty for the execution-oriented management team.
📌 (4) Axis Q8-A4 Score:1
Q8-A4-1. What Growth Hurdle Does the Market Demand From Haemonetics? (Reverse DCF Alternative)
(3) Axis Q8-A3 (Historical Band Position): Undervalued
(4) Axis Q8-A4 (Justification for Growth): Undervalued
The valuation framework yields a definitive consensus, with three of the four primary axes (Key Indicators, Historical Band, and Growth Justification) pointing firmly in the direction of undervaluation, confirming a robust, reliable, and mathematically sound margin of safety.
Scoring Rationale: There are no exceptional or paradigm-shifting factors outside the scope of the standard operational metrics that warrant a manual override of the mechanical valuation score; the core metrics accurately and fully capture the corporate reality.
Commentary: The rigorous mechanical valuation framework reveals a high-quality compounder that is currently trading at a distinct, measurable discount to its historical cash flow multiples. While perfectly in line with general med-tech peers on a forward basis, the market’s implied growth expectations completely fail to fully credit Haemonetics’ rapidly expanding, high-margin MedSurg runway.
Step 8 Summary: Haemonetics is fundamentally undervalued, offering a highly attractive entry point driven by compressed historical cash flow multiples and remarkably achievable growth hurdles.
💀 Step 9: What Are the Risks of Haemonetics? Fatal Risks & Pre-Mortem
Q9-A1. What Are the Biggest Risks to Haemonetics?
1 The Strategic Transition of CSL Plasma to Non-Exclusive Supply:
Cause: Haemonetics recently signed a non-exclusive agreement with its massive legacy customer, CSL Plasma, allowing CSL to diversify its hardware ecosystem away from a pure Haemonetics monopoly.
Impact: Financial (Margin compression and severe volume loss in the core Apheresis segment if CSL aggressively adopts competitor devices at scale).
Mitigation/Monitoring Indicators: Monitor quarterly Apheresis organic growth and the sustained, measurable adoption rate of the yield-boosting Persona PLUS software, which acts as a highly sticky counterweight to customer churn.
2 Interest Expense Drag from Elevated Acquisition Debt:
Cause: Following the aggressive cash acquisitions of OpSens and Vivasure to build out the MedSurg portfolio, the company sits on $1.17 billion in total debt with a 2.69x leverage ratio.
Mitigation/Monitoring Indicators: Track quarterly free cash flow conversion rates and management’s unyielding commitment to using excess cash to pay down the revolving credit facility balances.
3 Vulnerability to Broad U.S. Tariff and Freight Headwinds:
Cause: The company maintains a highly complex global supply chain for raw medical plastics, resins, and electronics, making it acutely sensitive to geopolitical tariff disputes and soaring global freight rates.
Impact: Financial (Direct, unavoidable compression of gross margins, partially offsetting the accretive margin benefits of the MedSurg mix shift).
Mitigation/Monitoring Indicators: Watch for the successful execution of targeted, contractual price increases and the realization of promised tariff refunds in subsequent quarters.
Q9-A2. How Sensitive Is Haemonetics to the Economy?
1 U.S. Interest Rate Environment (⬇): Persistent, elevated borrowing costs dramatically increase the debt-servicing friction on Haemonetics’ $1.17 billion debt load, siphoning critical free cash flow away from shareholder returns and directly compressing its valuation multiple across institutional models.
2 U.S. Labor Market & Consumer Health (⬆/⬇): The plasma collection industry is uniquely counter-cyclical; during periods of severe macroeconomic stress or rising unemployment, donor foot traffic at plasma centers typically surges as individuals desperately seek supplemental income, inadvertently and massively boosting Haemonetics’ disposable sales volume.
Q9-A3. Haemonetics Pre-Mortem: What Could Go Wrong?
1 The Interventional M&A Strategy Collapses Under Regulatory Scrutiny: Haemonetics fails to secure final FDA PMA clearance for its highly touted Vivasure PerQseal technology, triggering massive write-downs, destroying its credibility in the hospital suite, and leaving the company stranded with high debt and an aging, low-growth plasma business.
Early Warning Signal: The company quietly announces “extended FDA data requests” or delays the projected commercialization timeline during a quarterly earnings call, sparking immediate analyst downgrades.
2 Competitors Crack the Plasma Software Code: Rivals like Terumo BCT successfully launch a copycat donor-management software that exactly matches the yield improvements of Persona PLUS, instantly breaking Haemonetics’ moat and sparking a brutal, race-to-the-bottom price war on plastic disposables.
Early Warning Signal: CSL Plasma announces a massive, fleet-wide order of competitor hardware, decisively and permanently shifting volume away from the NexSys PCS ecosystem.
3 A Severe Supply Chain Disruption Halts Disposables Production: A sudden geopolitical event or raw material resin shortage cripples the company’s ability to manufacture its proprietary plasma bowls and tubing, forcing collection centers to halt operations and instantly destroying Haemonetics’ recurring revenue stream.
Early Warning Signal: Management drastically lowers annual organic growth guidance, citing “severe inventory constraints” and “unprecedented freight logistics challenges.”
Q9-A4. Risk Adjustment Score
Reason for Scoring: The identified risks, particularly the CSL Plasma transition and the heavy acquisition-related debt load, are actively recorded in current guidance and present a measurable drag on bottom-line expansion. However, management’s aggressive pivot toward the high-margin MedSurg segment and flawless cash flow conversion render these risks entirely controllable, keeping the penalty confined to the qualitative concern tier.
📊 Risk Adjustment Score:-4 pts
Step 9 Summary: Haemonetics faces legitimate, undeniable friction from customer concentration transitions and acquisition-related debt, but its unassailable cash generation and strategic diversification ensure these risks remain manageable hurdles rather than existential threats.
🎯 Step 10: Haemonetics Final Verdict: Score & Rating
Commentary: The exceptional durability of the recurring plasma revenue base, combined with phenomenal cash conversion and a rapidly accelerating interventional cardiology portfolio, drives a commanding foundational score. The disciplined valuation framework awards a premium for the stock’s discounted cash flow multiple, perfectly offsetting the minor structural friction caused by customer transitions and acquisition debt.
Q10-A2. Should You Buy Haemonetics? (Recommendation)
Recommendation:Buy
Commentary: Driven by a highly defensible economic moat, an aggressive transition toward double-digit growth hospital markets, and a management team relentlessly retiring shares, the company offers a highly compelling, cash-rich compounding profile at a distinct discount to its historical intrinsic value.
Q10-A3. Investment Thesis in One Line
Haemonetics is rapidly evolving from a steady, cash-cow plasma tollbooth into a high-margin medical technology compounder, trading at an attractive valuation discount, though investors must vigilantly monitor the margin friction stemming from its recent debt-funded acquisition spree.
Q10-A4. Haemonetics’s Price Trend & Key Drivers
Stock Price Trends Over the Past 12 Months:Sideways movement ➡️
June 05, 2026Financial Reporting Segment Reorganization
Description: Management realigned the company into Apheresis and MedSurg segments, providing Wall Street with crystal-clear visibility into the underlying profitability and explosive growth of the hospital portfolio, stabilizing sentiment during a highly volatile macro period. ➡ Sideways Consolidation
August 06, 2026Q1 2027 Earnings Beat and Guidance Raise
Description: The company demolished expectations with an adjusted EPS of $1.14 and stunning 25% growth in North American plasma disposables, prompting management to raise full-year organic growth guidance and sparking a massive wave of analyst upgrades. ➡ Stock Price Surge
August 14, 2026CSL Plasma Supply Agreement Execution
Description: While strictly non-exclusive, securing a definitive operational agreement with its largest legacy customer removed a massive cloud of uncertainty regarding future volume erosion, cementing the absolute floor for the Apheresis segment’s cash flow. ➡ Steady Uptrend
Q10-A5. Action Plan
Current Price:$108.44
Buy Zone:$90.00 ($85.00–$95.00)
(1) Calculation of Fundamental Value: From the perspective of securing the ‘Margin of Safety,’ we anchor the buy zone to the stock’s historical P/FCF support levels and the lower bounds of its recent 52-week consolidation phase, ensuring entry at a multiple that heavily discounts the ongoing, restrictive debt burden.
(2) Momentum Premium/Discount Application: Given the massive post-earnings surge and broad analyst upgrades, the stock is currently riding intense technical momentum; we strictly adhere to the conservative intrinsic value, requiring a market pullback to bleed off the current technical overextension.
(3) Conclusion: Present the appropriate buying price range (narrow band) calculated through the above process, and present the midpoint of the band based on the appropriate buying price. We demand a retreat to the $90 level, enforcing strict valuation discipline before aggressively accumulating shares.
Price Target:$115.00
Expected Return:+6.0% (vs. current price)
📍 Select target stock price calculation criteria:
Forward P/E Ratio — The most accurate metric to capture the market’s assessment of Haemonetics’ near-term earnings power and MedSurg margin expansion.
🧮 Price Target Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): $5.75 × 20.00 = $115.00
Basis for applying the multiple: Forward P/E Peer Average — 20.00x — Applied at parity with the broader mid-cap medical device peer group, reflecting normalized execution without an aggressive growth premium.
Conditions and timing for reaching price target: The price target realization is tethered to the Q2 and Q3 FY27 earnings releases, specifically requiring confirmation that MedSurg operating margins are expanding past the 25% threshold and debt leverage falls below 2.5x.
Stop Loss:$75.00 ($70.00–$80.00)
Action trigger upon catalyst achievement:
1 Persona PLUS software officially crosses a 10% global yield improvement threshold
Description: This confirms the software’s unassailable pricing power, mechanically lifting corporate gross margins and demanding an immediate, substantial multiple expansion. 👉 Increased Holdings (Buy)
2 Vivasure Medical receives full, unmitigated FDA Premarket Approval
Description: The approval unlocks a massive new TAM in structural heart closures, validating the M&A strategy and requiring an aggressive upward revision of outer-year EPS estimates. 👉 Increased Holdings (Buy)
3 Management executes early, aggressive paydown of the revolving credit facility
Description: Rapid deleveraging proves that free cash flow conversion remains elite, destroying the primary bear thesis and allowing the market to re-rate the stock as a pristine balance sheet compounder. 👉 Hold
Action trigger upon risk realization:
1 CSL Plasma announces an exclusive, fleet-wide transition to a competitor’s hardware
Description: The loss of the ultimate anchor customer shatters the Apheresis cash flow model, immediately invalidating the capital allocation thesis that funds MedSurg growth. 👉 Liquidation (Strong Sell)
2 Quarterly gross margins permanently compress below 55% due to untamable freight and tariff costs
Description: The failure to pass costs onto the highly consolidated plasma fractionators breaks the operating leverage narrative, necessitating a highly defensive posture. 👉 Reduction in Holdings (Sell)
3 The FDA issues a Class I recall for the VASCADE MVP XL system
Description: The sudden destruction of the crown jewel in the Interventional Technologies portfolio halts the company’s highest-margin growth engine entirely. 👉 Liquidation (Strong Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Avoid buying at the current momentum-driven peak; deploy capital only if macro market turbulence drags the stock back down into the strict $85-$90 safety zone, sizing positions conservatively.
Neutral Investors: Initiate a small, foundational 1/3 starter position here to capture ongoing earnings momentum, but ruthlessly hold the remaining capital in reserve to aggressively average down if tariff headwinds cause a quarterly miss.
Aggressive Investors: Capitalize on the massive analyst upgrade cycle by buying directly into the current breakout, utilizing tight trailing stop-losses just below the 50-day moving average to protect against sudden M&A integration hiccups.
🕵️♂️ Deep Dive Analysis
Q1: Is Haemonetics’ Exposure to the CSL Plasma Transition Its Biggest Weakness?
Analysis: For years, Haemonetics operated as the undisputed, monopolistic supplier of plasma collection hardware to the industry’s titans. The recent pivot of CSL Plasma—one of its largest and most lucrative customers—toward a non-exclusive supply agreement represents a seismic structural shift in the industry landscape. By deliberately diversifying its hardware ecosystem, CSL threatens to commoditize the collection process, putting extreme pressure on Haemonetics’ disposable pricing. However, the data reveals a highly nuanced defense: Haemonetics’ Q1 FY27 North American plasma disposables surged 25% despite this transition. This definitively indicates that while exclusivity is gone, the sheer operational superiority of the NexSys PCS ecosystem and the yield-boosting power of Persona PLUS software make competitor displacement incredibly difficult and economically painful for the centers.
Judgment:Neutral — The loss of exclusivity undeniably strips Haemonetics of absolute pricing power and introduces volume risk, but the sticky, yield-generating superiority of its proprietary software effectively mitigates catastrophic churn, rendering it a manageable headwind rather than a fatal weakness.
Q2: Can Haemonetics’ 19.3x Forward P/E Be Justified by the MedSurg Segment Expansion?
Analysis: A 19.3x forward earnings multiple implies that the market demands consistent, highly predictable growth from a mature company. While the legacy plasma business alone (growing at low-to-mid single digits) cannot mathematically justify this premium, the newly reorganized MedSurg segment entirely rewrites the valuation math. MedSurg, encompassing Vascular Closure and Hemostasis Management, is compounding at high single to double digits. Furthermore, products like the VASCADE MVP XL carry vastly superior gross margins compared to bulk plastic disposables. As MedSurg mathematically becomes a larger percentage of total revenue (currently 44% and climbing), its superior margin profile mechanically pulls the entire corporate operating margin upward.
Judgment:Fairly Valued — The 19.3x multiple perfectly captures the ongoing fundamental mix shift; it appropriately prices in the high-growth, high-margin reality of the MedSurg hospital suite without pushing into the irrational “priced for perfection” territory (30x+) typical of pure-play robotic surgery or structural heart startups.
Q3: Will the Apheresis Restructuring Obscure Underlying Plasma Growth Deceleration?
Analysis: In June 2026, management combined the massive Plasma segment and the struggling Blood Center segment into a single “Apheresis” reporting unit. Skeptics naturally argue this is a classic accounting sleight-of-hand designed to blend the decelerating legacy blood business with the stable plasma business, obscuring weakness in both. However, management has explicitly committed to maintaining supplemental revenue disclosures for both Plasma and Other (Blood Center) components within their earnings materials. The Q1 FY27 results proved this out, explicitly detailing an 8.2% organic growth rate in Plasma against a 2.8% decline in Other.
Judgment:Negative — The restructuring makes internal resource allocation more efficient and accurately reflects the unified technological base, and the deliberate preservation of supplemental line-item disclosures entirely destroys the bearish narrative that management is attempting to hide decelerating legacy segments.
Q4: How Secure is Haemonetics’ Moat in the Viscoelastic Testing (TEG) Market?
Analysis: Within the Blood Management Technologies portfolio, the TEG (Thromboelastography) franchise is a quiet, highly profitable powerhouse, consistently delivering mid-teens growth. The moat here is built entirely on workflow entrenchment. TEG analyzers provide critical, real-time assessment of a patient’s overall hemostasis (clotting ability) during traumatic surgeries. Once a hospital protocol integrates TEG software into its trauma and cardiovascular workflows, the switching costs become prohibitive. The recent launch of the TEG 6s Global Hemostasis-HN assay cartridge further deepens this moat, allowing hospitals to expand testing capabilities without buying new hardware.
Judgment:Positive — The moat is exceptionally deep; driven by capital equipment lock-in and high-margin recurring reagent cartridges, the TEG franchise acts as an impenetrable, high-cash-flow fortress within the broader MedSurg segment.
Analysis: Haemonetics executed a hyper-aggressive M&A strategy to build its MedSurg unit, acquiring OpSens for $345 million and Vivasure for up to €185 million. This spree ballooned total debt to $1.17 billion and pushed net leverage to 2.69x EBITDA. In a sustained high-interest-rate macro environment, this debt burden acts as a heavy anchor, devouring cash through interest expense ($20.8 million linked to the 2029 notes alone). While the company boasts an elite 89% free cash flow conversion rate that ensures absolute solvency, the sheer size of the debt absolutely restricts management’s ability to execute further massive, transformational acquisitions without risking severe credit rating downgrades.
Judgment:Negative — The balance sheet has been fully tapped to fund the current iteration of the MedSurg pipeline; until management aggressively deleverages the revolving credit facility, the company is effectively sidelined from major strategic M&A, forcing total reliance on internal organic execution.
Q6: Can the Vivasure Medical Acquisition Meaningfully Accelerate Interventional Technologies?
Analysis: The acquisition of Vivasure Medical brings the PerQseal technology—a fully absorbable, patch-based closure system—into Haemonetics’ portfolio. Currently, Haemonetics dominates venous closure (via VASCADE) but lacks a killer application in large-bore arterial closure. If PerQseal achieves FDA PMA clearance, it bridges this massive product gap, allowing Haemonetics sales reps to bundle venous and arterial closure systems to hospital procurement boards. This creates a lethal cross-selling synergy that directly attacks the flanks of cardiovascular giants like Abbott.
Judgment:Positive — The Vivasure acquisition is the critical missing puzzle piece for the Interventional Technologies division; assuming successful FDA clearance, it dramatically expands the TAM and fortifies the company’s competitive positioning in comprehensive vascular closure.
Q7: Are U.S. Macroeconomic Labor Trends a Structural Threat to Plasma Collection Volumes?
Analysis: The U.S. supplies roughly two-thirds of the world’s source plasma, heavily relying on the financial incentivization of donors. Historically, plasma collection is a counter-cyclical industry; during economic booms with high employment and rising wages, donor foot traffic wanes, threatening collection volumes. As the U.S. economy averts recession and labor markets remain historically tight, the marginal propensity for individuals to donate plasma for supplemental income drops. However, Haemonetics’ Persona PLUS software—which customizes collection to safely extract higher yields per donor—acts as a perfect operational hedge against lower foot traffic.
Judgment:Neutral — Tight labor markets undeniably threaten raw donor volume, but Haemonetics has ingeniously engineered a software solution that extracts more value from a shrinking donor pool, perfectly insulating its revenue stream from macro labor fluctuations.
Q8: How Effectively is Persona PLUS Monetizing the Existing NexSys PCS Installed Base?
Analysis: The genius of the Persona PLUS rollout is its capital-light nature. Haemonetics already incurred the heavy CapEx of installing the NexSys PCS hardware across global centers. Persona PLUS is a proprietary software overlay that utilizes complex algorithms to individualize collection, yielding over 5% more plasma per session. This presents a no-brainer ROI for the collection centers, who happily pay a premium for the software because the value of the extra plasma heavily outweighs the subscription cost. This transforms Haemonetics from a low-margin hardware vendor into a high-margin SaaS and disposables ecosystem.
Judgment:Positive — Persona PLUS represents the ultimate realization of the razor-and-blade model, seamlessly turning a static, commoditized hardware installed base into an expanding, high-margin software revenue stream.
Q9: Is the Current 6.56% Short Interest Indicative of Hidden Institutional Doubts?
Analysis: A short interest of 6.56% with 4.57 days-to-cover is not a screaming “short squeeze” setup, but it is elevated enough to signal that a dedicated cohort of sophisticated bears exists. The thesis for these shorts is almost certainly rooted in a “sum-of-the-fears” narrative: they are betting that the CSL Plasma transition will accelerate faster than expected, that the $1.17B debt load will choke free cash flow via variable interest, and that MedSurg margins will crack under the weight of global tariffs.
Judgment:Negative — The short interest is a highly rational, calculated bet against the company’s execution perfection. If management misses a single quarter of margin expansion, this short cohort is perfectly positioned to ruthlessly punish the stock’s current multiple.
Q10: Can Haemonetics Sustain Mid-Teens Disposables Growth in Hemostasis Management?
Analysis: The Q1 FY27 report highlighted mid-teens disposables growth in Hemostasis Management (TEG). Sustaining this blistering pace requires constant expansion of testing protocols beyond standard cardiovascular surgeries into broader trauma, liver transplant, and obstetrics applications. The recent global rollout of the HN-cartridge in EMEA and Japan proves that the company is actively opening new geographic and procedural frontiers for its existing installed base.
Judgment:Positive — The continuous introduction of specialized, FDA-cleared assay cartridges ensures that the existing TEG hardware footprint generates compounding, recurring revenue at a mid-teens clip, fully validating the long-term MedSurg growth thesis.